primary endpoints – Page 2 – Communicable Diseases Research

Vitamin D Status and SARS-CoV-2 Infection and COVID-19 Clinical Outcomes

Public Health

Published on 2021-12-222022-10-31
Journal: Frontiers in Public Health
[Category] COVID-19, MERS, SARS,

Teleconsultation for preoperative evaluation during the coronavirus disease 2019 pandemic: A technical and medical feasibility study

2019년 코로나바이러스 전염병 동안 수술 전 평가를 위한 원격 상담: 기술 및 의학적 타당성 조사

Clinical Trial

Published on 2021-12-012022-09-11
Journal: European journal of anaesthesiology
[Category] SARS, 임상, 치료기술,

[키워드] adverse events assigned Atrial fibrillation Care clearance Complete coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 pandemic effective Elective surgery Endpoint feasibility feasible FIVE Germany help implementation Implementation study Infection limit lockdown maintain majority Medical care medical service medical services one patient outcome Patient Patient education patient safety patients physical contact platform preoperative evaluation primary endpoints receive Registered risk Risk assessment Satisfaction subsequent surgery the patient Travel travel time university hospital yielding
[DOI] 10.1097/EJA.0000000000001616 PMC 바로가기 [Article Type] Clinical Trial

Knowledge Update on the Economic Evaluation of Pacemaker Telemonitoring Systems

심박 조율기 원격 모니터링 시스템의 경제성 평가에 대한 지식 업데이트

Review

Published on 2021-11-182022-09-10
Journal: International Journal of Environmental Research an
[Category] MERS, SARS, 치료기술,

[키워드] absence accelerated addition age Analysis applied Atrioventricular block Author cardiovascular event Cardiovascular events Characteristics coded Complete Cost-benefit analysis COVID-19 pandemic database effective Effectiveness enrolled follow-up studies Formal Google Scholar growth Health health-related quality of life healthcare worker Healthcare workers healthy hospital implantation inclusion criteria increasingly knowledge language life long term measurement medium Methodological quality MOST no significant difference no significant differences outcomes pacemaker pacemakers Patient patients performed physical contact presence or absence primary endpoints problems Quality of life randomized clinical trials reduced reduction in reliability remote telemonitoring Sample size searched Secondary endpoints Sex significantly study duration System systematic review Telemedicine treated variable without affecting
[DOI] 10.3390/ijerph182212120 PMC 바로가기 [Article Type] Review

Definitions and elements of endpoints in phase III randomized trials for the treatment of COVID-19: a cross-sectional analysis of trials registered in ClinicalTrials.gov

COVID-19 치료를 위한 3상 무작위 시험에서 평가변수의 정의 및 요소: ClinicalTrials.gov에 등록된 시험의 횡단면 분석

Research

Published on 2021-11-082022-09-10
Journal: Trials
[Category] MERS, SARS, 임상,

[키워드] achievement allocation Analysis Characteristics of endpoints Clinical course clinical trial clinical trials collected condition conducted Consensus COVID-19 COVID-19 treatments cross-sectional analysis Definition Diseases downloaded element Endpoint endpoints examined facilitate Frame inclusion criteria Infectious diseases information median non-severe patient non-severe patients phase Phase III trials primary endpoints Primary outcome measures provide randomized trial Registered Result Sample size secondary secondary endpoint secondary outcome measures selected severe and non-severe patients Severe patient severe patients severity time Time frame time frames transcribed Treatment Trial worsening
[DOI] 10.1186/s13063-021-05763-y PMC 바로가기 [Article Type] Research

Association between chronic hepatitis B infection and COVID-19 outcomes: A Korean nationwide cohort study

만성 B 형 간염 감염과 COVID-19 결과의 연관성 : 한국 전국 코호트 연구

Research Article

Published on 2021-10-052022-09-10
Journal: PLoS ONE
[Category] B형 간염, MERS, 치료제,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjusted odds ratio Antiviral antiviral agent Antiviral agents Antiviral treatment association CHB chronic hepatitis Chronic Hepatitis B Clinical outcome cohort study Coinfection collected Comorbidities Comorbidity Control coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 negative COVID-19 positive patient database disease severity Endpoint entecavir greater HBV Health Insurance Infection infection rate infection rates insurance Korean lead National Health Insurance negative controls Patient positive positive patients primary endpoints proportion random reduced respiratory Result risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 positivity SARS-CoV-2 test selected service severe acute respiratory syndrome Coronavirus statistically susceptibility target population tenofovir test result tested Treatment with infection worse prognosis
[DOI] 10.1371/journal.pone.0258229 PMC 바로가기 [Article Type] Research Article

Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial

청소년 및 노인의 SARS-COV-2 재조합 스파이크 단백질 백신 (NVX-COV2373)의 상이한 용량 요법 : 2 상 무작위 위약 대조 시험

Clinical Trial

Published on 2021-10-012022-08-13
Journal: PLoS Medicine
[Category] Biochemistry, MERS, SARS, 임상, 진단,

[키워드] 95% CI 95% confidence interval accumulate addition Administered Adults adverse events age Anti-spike Antibody Response assessments assigned composed conducted convalescent sera coronavirus Day dose dose regimen Efficacy Endpoint Enrollment exceeded Follow-up Formica Frequency full-length SARS-CoV-2 geometric mean geometric mean titer geometric mean titers GMTs group groups identify IgG immune persistence immune response immune responses immunogenic immunogenicity Immunoglobulin Immunoglobulin G include inhibitory concentration intensity intramuscular dose lack limitation Matrix-M1 adjuvant median Mild mild to moderate moderate neutralizing antibody Neutralizing antibody response neutralizing antibody responses NVX-CoV2373 occurred less Older Older adults participant Participants Phase 1 Phase 2 Placebo placebo-controlled placebo-controlled trial primary endpoints Protein Randomized randomized placebo-controlled trial Randomly reactogenicity receive Recombinant spike protein regimen researcher respiratory Respiratory Coronavirus robust safety follow-up SARS-CoV-2 second dose second vaccination secondary endpoint seroconversion rate seroconversion rates severity short duration spike glycoprotein spike glycoproteins Spike protein Support The United States These data Tolerability Treatment Trial Trial registration trimeric United States USA vaccination Vaccine vaccine group wild-type virus
[DOI] 10.1371/journal.pmed.1003769 PMC 바로가기 [Article Type] Clinical Trial

Anti-COVID property of subcutaneous ivermectin in synergy with zinc among midlife moderately symptomatic patients: a structured summary of a study protocol for a randomised controlled trial

중년의 중등도 증상 환자에서 아연과 시너지 효과를 나타내는 피하 이버멕틴의 항-COVID 특성: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-09-062022-09-10
Journal: Trials
[Category] SARS, 임상,

[키워드] 30-Day mortality absence activities approved Arm blinded calculated Chest clinic clinical co-morbidities co-morbidity comparator coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 symptom Data collection death dissemination doctor ECMO Effectiveness element Endpoint enrolment Evidence evidence of excluded FIVE GRADE Grade 1 grade 3 Grade 5 group groups high resolution high resolution CT high-flow oxygen therapy Hospitalized HRCT Infection institutional review board Intention Invasive mechanical ventilation Ivermectin lung lobe mechanical ventilation morbidities nasal no evidence of noninvasive normal saline number objective outcome outcome assessor outcome assessors oxygen Oxygen therapy oxygen) Pakistan participant Patient patient recruitment patients with moderate PCR Physicians Placebo placebo group placebo-controlled positive pregnant women presence or absence primary care primary endpoints protocol radiological improvement randomisation randomised randomised controlled trial Randomized randomized clinical trial Randomly receive recorded Registered reported requiring supplemental oxygen Sample size SARS-CoV-2 SARS-CoV-2 clearance secondary endpoint seven-point scale severe respiratory syndrome severity Standard standard care status Study protocol Subcutaneous Ivermectin supplemental oxygen supplementary material symptomatic synergy Trial website Zinc
[DOI] 10.1186/s13063-021-05487-z PMC 바로가기 [Article Type] Letter

Soluble Urokinase Plasminogen Activator Receptor as a Decision Marker for Early Discharge of Patients with COVID-19 Symptoms in the Emergency Department

응급실에서 COVID-19 증상이 있는 환자의 조기 퇴원을 위한 결정 마커로서의 가용성 Urokinase Plasminogen Activator Receptor

Observational Study

Published on 2021-09-012022-09-11
Journal: The Journal of emergency medicine
[Category] Coronavirus, SARS, 바이오마커, 임상,

[키워드] activator acute respiratory syndrome acute respiratory syndrome coronavirus Admission Better Biomarker C-reactive protein calculated can be used Care cohort study confirmed COVID-19 patients coronavirus COVID-19 COVID-19 pandemic COVID-19 patients COVID-19 symptoms CRP cut-off decision Department discharge discharged disease duration of symptom Early discharge Early warning score ED overcrowding electronic patient record Electronic patient records Emergency emergency department Endpoint evaluate Health Health care identify intubation marker measure Mild moderate National Early Warning Score NEWS Observational cohort study pandemic parameter Patient patient records patients patients with COVID-19 plasminogen point-of-care point-of-care test predicted Predictive Predictive value presenting primary endpoints receiver operating characteristics receptor respiratory Result review risk risk stratification ROC Safe SARS-CoV-2 score severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 severe disease shown strain suPAR suPAR. Symptom symptoms of COVID-19 trajectory Triage urokinase was measured was used with COVID-19
[DOI] 10.1016/j.jemermed.2021.03.012 PMC 바로가기 [Article Type] Observational Study

Comparative therapeutic efficacy of interferon alfa-2b and combination lopinavir/ritonavir plus interferon alfa-2b against SARS-CoV-2

SARS-COV-2에 대한 인터페론 ALFA-2B 및 조합 Lopinavir/Ritonavir Plus 인터페론 ALFA-2B의 비교 치료 효능

Research Article

Published on 2021-08-302022-09-10
Journal: BMC Infectious Diseases
[Category] SARS, 치료제,

[키워드] Adult patients adverse event adverse events antiviral drug antiviral drugs assigned association benefit clearance Clinical characteristics clinical monitoring Combination Comparative confidence interval coronavirus disease Coronavirus disease 2019 Coronavirus disease 2019 (COVID-19) COVID-19 Cox proportional hazard Cox proportional hazards regression disease Efficacy and safety evaluate faster group incidence individual Infection interferon interferon alfa-2b Lopinavir Lopinavir/ritonavir Nasopharyngeal swab no significant difference no significant differences not significantly different outbreak outcome oxygen oxygen support Patient patients hospitalized patients with SARS-CoV-2 PCR Pneumonia primary endpoint primary endpoints public health required Result retrospective cohort study Ritonavir SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 RNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) significant differences standard care group standard supportive care Symptom therapeutic efficacy therapy three group three groups Treatment treatment guideline treatment guidelines triggered virus virus clearance were assessed with COVID-19
[DOI] 10.1186/s12879-021-06595-6 PMC 바로가기 [Article Type] Research Article

Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19

초기의 후기 회복기 혈장은 중등도에서 세상에서 더 나은 생존과 관련이 있습니다.

Research Article

Published on 2021-07-282022-09-10
Journal: PLoS ONE
[Category] MERS, SARS, 임상,

[키워드] addressed administration administration of CCP Analysis CCP CCP administration Cohort Complete conducted convalescent plasma coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 convalescent plasma COVID-19 infection days alive discharge disease Endpoint Follow-up had more hospital hospital discharge Hospital mortality Hospital stay IMPROVE in-hospital mortality Inpatient investigated likelihood Limited mechanical ventilation median moderate-to-severe COVID-19 Mortality on mechanical ventilation outcome Patient plasma primary endpoint primary endpoints Propensity score question receive recipient recipients Research question Result secondary Secondary endpoints Study design survival therapeutic therapeutic option transfused trials ventilator WHO
[DOI] 10.1371/journal.pone.0254453 PMC 바로가기 [Article Type] Research Article